Kor Pulmonale

01Pathophysiology

Cor pulmonale is defined as right ventricular structural change (hypertrophy, dilation, or both) and eventual functional failure caused by pulmonary hypertension that originates from diseases of the lung parenchyma, the pulmonary vasculature, or the chest wall. The critical conceptual boundary is that left-sided heart disease and congenital heart disease are explicitly excluded from this definition. If the right ventricle fails because of mitral stenosis or left ventricular dysfunction causing backward pressure into the pulmonary circuit, that is simply right heart failure, not cor pulmonale.

The central mechanism begins with chronic alveolar hypoxia. In conditions like COPD, widespread destruction of alveolar-capillary units and chronic hypoxemia trigger hypoxic pulmonary vasoconstriction (HPV), a physiologic reflex that shunts blood away from poorly ventilated alveoli. When hypoxia is regional and temporary, HPV is protective; when it is global and sustained, the result is a widespread increase in pulmonary vascular resistance (PVR). In addition to vasoconstriction, chronic hypoxia promotes vascular remodeling: smooth muscle hypertrophy in the media of pulmonary arterioles, intimal fibrosis, and in-situ thrombosis. Hypercapnia and acidosis potentiate the vasoconstrictive effect. These structural changes make the elevated PVR partially irreversible over time.

As PVR rises, the right ventricle must generate higher pressures to maintain forward flow through the pulmonary circuit. The RV, which is a thin-walled, compliant chamber designed for a low-pressure system, responds initially with concentric hypertrophy. This compensatory phase can persist for years, and the patient may be asymptomatic or have only exertional limitations. However, once the RV can no longer compensate, it begins to dilate, wall stress increases (per the Law of Laplace), and RV systolic function deteriorates. RV dilation pulls the tricuspid annulus apart, producing functional tricuspid regurgitation, which further volume-overloads the RV and creates a vicious cycle of dilation, regurgitation, and worsening failure.

The downstream consequence of RV failure is systemic venous congestion: elevated central venous pressure manifests as JVD, hepatomegaly (congestive hepatopathy), ascites, and peripheral edema. Importantly, the lungs often remain relatively clear on auscultation because the problem is upstream of the left heart. This distinction, JVD and edema with clear lung fields, is a classic exam clue that points toward right-sided failure rather than left-sided or biventricular failure.

Another concept frequently tested is the role of polycythemia in chronic hypoxic lung disease. Sustained hypoxemia stimulates erythropoietin release, increasing red cell mass and blood viscosity, which further raises PVR and worsens pulmonary hypertension.

02Classification and Clinical Manifestation

Cor pulmonale can be classified by acuity and by the underlying mechanism producing pulmonary hypertension.

Classification by Acuity

Classification by Underlying Mechanism

Clinical Manifestation by Stage

03Diagnostic Workup

When a clinical vignette presents a patient with chronic lung disease who develops signs of right heart failure, the first step is to confirm that the right ventricle is structurally and functionally abnormal and to estimate pulmonary artery pressure. Transthoracic echocardiography is the best initial test because it is noninvasive, widely available, and directly visualizes RV size, wall thickness, septal motion, and tricuspid regurgitation jet velocity (from which RV systolic pressure is estimated using the modified Bernoulli equation: $\mathrm{\Delta }P=4v^2\backslash Delta\; P\; =\; 4v^2$). It also evaluates left heart structure and function, helping to exclude left-sided causes of pulmonary hypertension.

If echocardiography confirms suspected pulmonary hypertension and the clinical picture warrants further characterization (for example, if the patient is being considered for advanced therapies or the etiology is unclear), right heart catheterization is performed. RHC is the gold standard because it directly measures pulmonary artery pressures, cardiac output, and pulmonary capillary wedge pressure (PCWP). A PCWP $\le 15\backslash leq\; 15$ mmHg with elevated mean PAP ($\ge 20\backslash geq\; 20$ mmHg) confirms precapillary pulmonary hypertension, which is the hemodynamic hallmark of cor pulmonale. If PCWP is elevated, the pulmonary hypertension is postcapillary (left heart disease), and the diagnosis is not cor pulmonale.

Supporting tests include ECG (look for P pulmonale and right axis deviation), CXR (look for enlarged pulmonary arteries with a background of underlying lung disease), ABG (quantify hypoxemia and hypercapnia), PFTs (identify and categorize the underlying pulmonary process), and BNP (elevated in RV strain, useful for risk stratification).

When the underlying etiology is not obvious from history and PFTs, consider a V/Q scan to screen for CTEPH, which is a treatable cause. If the V/Q scan shows mismatched defects, pursue CT pulmonary angiography or conventional pulmonary angiography. This is a high-yield testing sequence because CTEPH is the form of pulmonary hypertension that may be curable via pulmonary thromboendarterectomy (PTE).

04Management & Treatment

The single most important principle in managing cor pulmonale is to treat the underlying pulmonary disease aggressively, because that is the root cause of the elevated PVR. In the most common scenario (COPD-related cor pulmonale), optimizing bronchodilator therapy, smoking cessation, and pulmonary rehabilitation are foundational.

Supplemental oxygen is the cornerstone pharmacologic intervention for cor pulmonale due to chronic hypoxic lung disease. Two landmark trials (the Nocturnal Oxygen Therapy Trial and the Medical Research Council trial) demonstrated that long-term oxygen therapy used for at least 15 hours per day reduces mortality in hypoxemic COPD patients by attenuating hypoxic pulmonary vasoconstriction and lowering PVR. The target oxygen saturation is $\ge 88\text{–}90\mathrm{\%}\backslash geq\; 88\backslash text\{--\}90\backslash \%$. On the exam, if a question asks for the "next best step" in a COPD patient with cor pulmonale who is hypoxemic, the answer is almost always start or optimize supplemental oxygen.

Diuretics are used symptomatically for volume overload (edema, ascites, JVD). Loop diuretics such as furosemide are first-line. However, be cautious: the failing right ventricle is preload-dependent, and excessive diuresis can reduce cardiac output and cause hypotension or renal hypoperfusion. Aldosterone antagonists (spironolactone 25-50 mg/day) may be added as potassium-sparing agents and for their potential antifibrotic effects, but evidence in cor pulmonale is limited.

Pulmonary vasodilators are a major exam trap. They are the standard of care for WHO Group 1 pulmonary arterial hypertension (idiopathic PAH, connective tissue disease-associated PAH) and for inoperable CTEPH (riociguat). However, they are not routinely recommended for cor pulmonale caused by COPD or ILD (WHO Group 3). The reason is that pulmonary vasodilators can impair hypoxic vasoconstriction, redistributing blood flow to poorly ventilated alveoli and worsening V/Q mismatch and hypoxemia. This is a frequently tested concept.

For CTEPH (WHO Group 4), the treatment of choice is pulmonary thromboendarterectomy (PTE), a surgical procedure that can be curative. For patients who are not surgical candidates or who have persistent pulmonary hypertension after PTE, riociguat or balloon pulmonary angioplasty may be considered.

Avoid systemic vasodilators (calcium channel blockers) unless the patient has demonstrated vasoreactivity on acute vasodilator testing during RHC, which is relevant only in idiopathic PAH. Nonselective calcium channel blockers can cause systemic hypotension without meaningfully reducing PVR.

Digoxin has no clear mortality benefit in cor pulmonale and is associated with toxicity risk, particularly in hypoxemic patients. Its only reasonable indication in this context is rate control for concurrent atrial fibrillation.

05Differential Diagnosis & Distractors

06Traps & High-Yield Pearls

The most common way students lose points on cor pulmonale questions is by confusing right heart failure from lung disease with right heart failure from left heart disease. The vignette will often describe a patient with longstanding COPD or ILD who presents with new peripheral edema and JVD. Students may reflexively choose "congestive heart failure" and select left-sided heart failure treatments (ACE inhibitors, beta-blockers). The critical discriminator is the absence of pulmonary congestion: if the lungs are clear on exam and the chest X-ray shows no pulmonary edema, this is isolated right heart failure from pulmonary hypertension, and the answer is cor pulmonale.

A second major trap involves pulmonary vasodilators. Students who remember that pulmonary hypertension is treated with sildenafil, bosentan, or epoprostenol may select these for a COPD patient with cor pulmonale. This is incorrect. These agents are indicated for WHO Group 1 PAH and certain Group 4 CTEPH cases. In Group 3 pulmonary hypertension (due to lung disease), vasodilators can worsen V/Q mismatch and are not standard therapy. The correct answer in COPD-related cor pulmonale is supplemental oxygen.

A third trap concerns the role of right heart catheterization vs. echocardiography. The exam may ask for the "best initial test" vs. the "most accurate test." Echo is the best initial step; RHC is the gold standard but is invasive and reserved for when hemodynamic confirmation or treatment decisions require it. Do not jump to RHC as a first-line test.

Finally, watch for questions about acute cor pulmonale from a large pulmonary embolism. The S1Q3T3 pattern on ECG, acute RV dilation on echo, and McConnell sign (RV free wall akinesis with preserved apical contractility) are classic findings. The management here is fundamentally different: anticoagulation with heparin, and systemic thrombolytics or catheter-directed therapy if the patient is hemodynamically unstable. Do not confuse the chronic management of cor pulmonale with the acute treatment of a PE-related RV failure.

The core competency being tested with cor pulmonale is the ability to recognize isolated right heart failure in the setting of chronic lung disease, sequence the diagnostic workup correctly (echo first, RHC for confirmation), identify that oxygen therapy is the intervention with proven survival benefit in hypoxic cor pulmonale, and avoid the trap of prescribing pulmonary vasodilators for Group 3 pulmonary hypertension.